AstraZeneca announced that the glycopyrrolate/formoterol fumarate (Bevespi Aerosphere) inhaler is now available.
The FDA approved Bevespi Aerosphere in April 2016. The medication is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or for the relief of acute bronchospasm.
Glycopyrrolate/formoterol fumarate 9 mcg/4.8 mcg is a